Bifogade filer
20200831 - PR - Change in number of shares and votes - UK
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Danmark |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
PRESS RELEASE
August 31, 2020
During August, the registered number of shares and votes in Saniona AB (publ) (“Saniona”) has increased due to the directed share issue that was announced on August 10, 2020. As of August 31, 2020, the registered number of shares and votes in Saniona amounts to 61,043,690.
For more information, please contact
Rami Levin, President & CEO, Saniona, Mobile: +1 (781) 987 3144, Email: rami.levin@saniona.com
Anita Milland, Interim CFO & Head of IR, Saniona, Mobile +45-20163432. Email: anita.milland@saniona.com
This information is such information as Saniona AB (publ) is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out above, at 8 a.m. CET on August 31, 2020.
About Saniona
Saniona is a rare disease biopharmaceutical company focused on research, development and commercialization Saniona is a rare disease biopharmaceutical company focused on research, development and commercialization of treatments for the central nervous system. The company has four programs in clinical development. Saniona intends to develop and commercialize treatments for rare disease indications such as hypothalamic obesity and Prader-Willi syndrome on its own. The research is focused on ion channels and the company has a broad portfolio of research programs. Saniona also has out-licensing agreements with Boehringer Ingelheim GmbH, Productos Medix, S.A de S.V and Cadent Therapeutics. Saniona is based in Copenhagen, Denmark, and in Boston, US. The company’s shares are listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at www.saniona.com.